Supernus Pharmaceuticals, Inc. is a high-risk specialty pharmaceutical company based in the United States of America. They focus on developing and commercializing products for central nervous system diseases, including epilepsy, migraine, ADHD, and Parkinson's Disease. Their diverse neuroscience portfolio includes treatments like Trokendi XR, Oxtellar XR, and Qelbree. Supernus Pharmaceuticals, Inc. has an ESG score of 32, showcasing their commitment to environmental, sustainability, and governance practices.